Polymorphisms in XPD and hOGG1 and prostate cancer risk: A meta-analysis

Urologia Internationalis

Volumn 89, Issue 2, 2012, Pages 233-240

  Zhu, Shimiao ^a   Zhang, Hui ^b   Tang, Yang ^a   Wang, Jianmin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA GLYCOSYLTRANSFERASE; HUMAN OXOGUANINE GLYCOSYLASE 1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; CORRELATION ANALYSIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DNA GLYCOSYLASES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84864824039     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000339603     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10- 30.
2. Shields PG, Harris CC: Molecular epidemiology and the genetics of environmental cancer. JAMA 1991; 266: 681-687.
3. De Marzo AM, Marchi VL, Epstein JI, et al: Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992.
4. Khandrika L, Kumar B, Koul S, et al: Oxidative stress in prostate cancer. Cancer Lett 2009; 282: 125-136.
5. Sancar A, Tang MS: Nucleotide excision repair. Photochem Photobiol 1993; 57: 905-921.
6. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-1530.
7. Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1: 22-33.
8. Agalliu I, Kwon EM, Salinas CA, et al: Genetic variation in DNA repair genes and prostate cancer risk: Results from a population- based study. Cancer Causes Control 2010; 21: 289-300.
9. Dhillon VS, Yeoh E, Fenech M: DNA repair gene polymorphisms and prostate cancer risk in South Australia - results of a pilot study. Urol Oncol 2011; 29: 641-646.
10. Nock NL, Cicek MS, Li L, et al: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006; 27: 1842-1848.
11. Mandal RK, Gangwar R, Mandhani A, et al: DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: A study from North India. DNA Cell Biol 2010; 29: 183-190.
12. Lavender NA, Komolafe OO, Benford M, et al: No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 2010; 70: 113-119.
13. Handoll HH: Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 2006; 87: 875.
14. Bau DT, Wu HC, Chiu CF, et al: Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 2007; 27: 2893-2896.
15. Rybicki BA, Conti DV, Moreira A, et al: DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 23-29.
16. Gao R, Price DK, Dahut WL, et al: Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 2010; 10: 13-18.
17. Ritchey JD, Huang WY, Chokkalingam AP, et al: Genetic variants of DNA repair genes and prostate cancer: A population-based study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1703-1709.
18. Yun SJ, Ha YS, Chae Y, et al: The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Ann Oncol 2012; 23: 401-405.
19. Zhang J, Dhakal IB, Greene G, et al: Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: Effects modified by plasma antioxidants. Urology 2010; 75: 779-785.
20. Nam RK, Zhang WW, Jewett MA, et al: The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 2005; 11: 8391-8397.
21. Chen L, Elahi A, Pow-Sang J, et al: Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 2003; 170: 2471-2474.
22. Xu J, Zheng SL, Turner A, et al: Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 2002; 62: 2253-2257.
23. Zhou C: A Case-control study on the association between single nucleotide polymorphism (SNP) of ERCCZ/XPD and hOGGI and prostate cancer susceptibility. Hangzhou, Zhejiang University, 2011.
24. Kohno T, Shinmura K, Tosaka M, et al: Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998; 16: 3219-3225.
25. Kopec JA, Esdaile JM: Bias in case-control studies: A review. J Epidemiol Community Health 1990; 44: 179-186.